Amphastar Pharmaceuticals (AMPH) Long-Term Deferred Tax (2013 - 2026)

Amphastar Pharmaceuticals' Long-Term Deferred Tax history runs 14 years deep, the most recent figure standing at $42.5 million for Q1 2026.

• In Q1 2026, Long-Term Deferred Tax fell 40.3% year-over-year to $42.5 million; the TTM figure through Mar 2026 stood at $42.5 million (down 40.3% YoY), while the FY2025 annual figure was $42.5 million, down 40.3% from the prior year.
• Long-Term Deferred Tax was $42.5 million for Q1 2026 at Amphastar Pharmaceuticals, roughly flat from $42.5 million in the prior quarter.
• In the past five years, Long-Term Deferred Tax ranged from a high of $71.1 million in Q4 2024 to a low of $22.4 million in Q1 2022.
• Historically, Long-Term Deferred Tax has averaged $47.6 million across 5 years, with a median of $42.5 million in 2025.
• The sharpest annual moves came in 2023 and 2025: Long-Term Deferred Tax jumped 82.45% in 2023, then plunged 40.3% in 2025.
• A 5-year view of Long-Term Deferred Tax shows it stood at $38.5 million in 2022, then surged by 38.22% to $53.3 million in 2023, then jumped by 33.56% to $71.1 million in 2024, then plunged by 40.3% to $42.5 million in 2025, then changed by 0.0% to $42.5 million in 2026.
• The last three Long-Term Deferred Tax figures came in at $42.5 million (Q1 2026), $42.5 million (Q4 2025), and $71.1 million (Q3 2025), per Business Quant data.